Incidence and Predictors of New-Onset Silent Atrial Fibrillation after Coronary Artery Bypass Graft Surgery
Table 2
Clinical characteristics according to the occurrence of atrial fibrillation.
(%), median (interquartile range),
SR group
Silent AF group
Clinical AF group
mean ± SD
()
()
()
Surgery data
Number of CABG
0.55
1
1 (2)
0
1 (5)
2
11 (17)
3 (23)
7 (33)
3
28 (42)
6 (46)
6 (29)
4
22 (33)
3 (23)
5 (25)
5
4 (6)
1 (8)
1 (5)
6
0
0
1 (5)
CPB
35 (53)
5 (39)
10 (48)
0.61
CPB duration (min)
89 (75–109)
119 (103–145)
95 (75–113)
0.062
Aortic cross-clamp duration (min)
71 ± 22
96 ± 21
71 ± 19
0.062
ICU management
Mechanical ventilation duration (hours)
5 (4–7)
5 (4–6)
4 (3–5)
0.22
ICU stay duration (hours)
60 (27–91)
27 (19–91)
46 (24–89)
0.32
Norepinephrine
31 (47)
4 (31)
8 (38)
0.49
Inotropic catecholamine
5 (8)
3 (23)
6 (29)
0.032
Amiodarone
13 (20)
3 (23)
14 (67)
<0.001
Biological data
pH 3 hours after surgery
7.39 ± 0.06
7.38 ± 0.07
7.37 ± 0.05
0.22
pH 24 hours after surgery
7.37 ± 0.04
7.37 ± 0.04
7.37 ± 0.04
0.90
Troponin 3 hours after surgery, ng/mL
3.5 (0.9–5.8)
1.7 (0.5–6.7)
2.9 (0.4–6.3)
0.62
Troponin 24 hours after surgery, ng/mL
2.3 (1.7–5)
2 (1.2–5.3)
1.8 (1.1–3.4)
0.34
CRP peak, mg/L
194 ± 86
214 ± 84
197 ± 110
0.78
NT pro-BNP peak, pg/mL
150 (65–531)
136 (64–675)
168 (71–1947)
0.49
Lowest hemoglobin level, g/dL
9 (8.3–10)
9.1 (8.1–11.7)
9.6 (8.7–9.9)
0.42
In-hospital follow-up
Acute kidney injury (KDIGO stage 1)
20 (30)
4 (31)
9 (43)
0.56
Sepsis
1 (2)
0
3 (14)
0.025
Stroke
0
0
0
—
Myocardial infarction
3 (5)
0
0
0.45
Treatment at discharge
Betablockers
60 (91)
13 (100)
15 (75)
0.055
Calcium Channel Blockers
8 (12)
1 (8)
3 (14)
0.82
Statins
36 (96)
11 (85)
18 (90)
0.32
ACE inhibitors
52 (82)
11 (86)
12 (57)
0.17
VKA
0
1 (8)
8 (40)
<0.001
AF indicates atrial fibrillation; CABG: coronary artery bypass graft; CPB: cardio pulmonary bypass; CRP: C Reactive Protein; GDF: Grow Differentiation Factor; ICU: intensive care unit; NT Pro-BNP: N Terminal Pro-Brain Natriuretic Peptide; SD: standard deviation; SR: sinus rhythm; VKA: vitamin K antagonists. compared to SR group; compared to clinical AF group.
